Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Cidara Therapeutics Inc has a consensus price target of $38 based on the ratings of 8 analysts. The high is $46 issued by Citizens Capital Markets on March 12, 2025. The low is $33 issued by Guggenheim on November 8, 2024. The 3 most-recent analyst ratings were released by Citizens Capital Markets, HC Wainwright & Co., and Needham on March 12, 2025, March 10, 2025, and March 7, 2025, respectively. With an average price target of $38.67 between Citizens Capital Markets, HC Wainwright & Co., and Needham, there's an implied 72.70% upside for Cidara Therapeutics Inc from these most-recent analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
03/12/2025 | Buy Now | 105.45% | Citizens Capital Markets | Roy Buchanan36% | → $46 | Initiates | → Market Outperform | Get Alert |
03/10/2025 | Buy Now | 56.32% | HC Wainwright & Co. | Ed Arce60% | $24 → $35 | Maintains | Buy | Get Alert |
03/07/2025 | Buy Now | 56.32% | Needham | Joseph Stringer51% | $35 → $35 | Reiterates | Buy → Buy | Get Alert |
01/27/2025 | Buy Now | — | Cantor Fitzgerald | Eric Schmidt31% | — | Assumes | → Overweight | Get Alert |
12/13/2024 | Buy Now | 51.85% | RBC Capital | Gregory Renza47% | → $34 | Initiates | → Outperform | Get Alert |
12/05/2024 | Buy Now | 100.98% | WBB Securities | Stephen Brozak77% | $40 → $45 | Maintains | Strong Buy | Get Alert |
11/11/2024 | Buy Now | 7.19% | HC Wainwright & Co. | Ed Arce60% | $24 → $24 | Reiterates | Buy → Buy | Get Alert |
11/08/2024 | Buy Now | 47.39% | Guggenheim | Seamus Fernandez61% | → $33 | Initiates | → Buy | Get Alert |
10/22/2024 | Buy Now | 7.19% | HC Wainwright & Co. | Ed Arce60% | $24 → $24 | Reiterates | Buy → Buy | Get Alert |
09/16/2024 | Buy Now | 7.19% | HC Wainwright & Co. | Ed Arce60% | $24 → $24 | Reiterates | Buy → Buy | Get Alert |
08/14/2024 | Buy Now | 7.19% | HC Wainwright & Co. | Ed Arce60% | → $24 | Upgrade | Neutral → Buy | Get Alert |
08/14/2024 | Buy Now | — | Cantor Fitzgerald | Louise Chen56% | — | Reiterates | → Overweight | Get Alert |
08/14/2024 | Buy Now | 11.66% | Needham | Joseph Stringer51% | $25 → $25 | Reiterates | Buy → Buy | Get Alert |
06/20/2024 | Buy Now | — | Cantor Fitzgerald | Louise Chen56% | — | Reiterates | → Overweight | Get Alert |
05/16/2024 | Buy Now | 11.66% | Needham | Joseph Stringer51% | $25 → $25 | Reiterates | Buy → Buy | Get Alert |
04/25/2024 | Buy Now | 78.65% | WBB Securities | Stephen Brozak77% | → $40 | Maintains | Strong Buy | Get Alert |
04/25/2024 | Buy Now | 11.66% | Needham | Joseph Stringer51% | $3 → $25 | Maintains | Buy | Get Alert |
04/25/2024 | Buy Now | — | Cantor Fitzgerald | Louise Chen56% | — | Reiterates | → Overweight | Get Alert |
04/23/2024 | Buy Now | — | Cantor Fitzgerald | Louise Chen56% | — | Reiterates | → Overweight | Get Alert |
04/08/2024 | Buy Now | -73.2% | HC Wainwright & Co. | Ed Arce60% | $120 → $120 | Maintains | Buy | Get Alert |
12/07/2023 | Buy Now | -73.2% | HC Wainwright & Co. | Ed Arce60% | $6 → $120 | Reiterates | Buy → Buy | Get Alert |
11/06/2023 | Buy Now | -73.2% | HC Wainwright & Co. | Ed Arce60% | → $120 | Reiterates | Buy → Buy | Get Alert |
09/22/2023 | Buy Now | -86.6% | Needham | Joseph Stringer51% | → $60 | Reiterates | Buy → Buy | Get Alert |
09/22/2023 | Buy Now | -73.2% | HC Wainwright & Co. | Ed Arce60% | → $120 | Reiterates | Buy → Buy | Get Alert |
09/08/2023 | Buy Now | -86.6% | Needham | Joseph Stringer51% | → $60 | Reiterates | Buy → Buy | Get Alert |
09/07/2023 | Buy Now | -73.2% | HC Wainwright & Co. | Ed Arce60% | → $120 | Reiterates | Buy → Buy | Get Alert |
08/07/2023 | Buy Now | -73.2% | HC Wainwright & Co. | Ed Arce60% | → $120 | Reiterates | → Buy | Get Alert |
08/04/2023 | Buy Now | -86.6% | Needham | Joseph Stringer51% | → $60 | Reiterates | Buy → Buy | Get Alert |
08/01/2023 | Buy Now | -73.2% | HC Wainwright & Co. | Ed Arce60% | → $120 | Reiterates | → Buy | Get Alert |
08/01/2023 | Buy Now | -77.67% | Cantor Fitzgerald | Louise Chen56% | → $100 | Reiterates | Overweight → Overweight | Get Alert |
06/26/2023 | Buy Now | -73.2% | HC Wainwright & Co. | Ed Arce60% | → $120 | Reiterates | Buy → Buy | Get Alert |
05/15/2023 | Buy Now | -73.2% | HC Wainwright & Co. | Ed Arce60% | → $120 | Reiterates | Buy → Buy | Get Alert |
05/12/2023 | Buy Now | -86.6% | Needham | Joseph Stringer51% | → $60 | Reiterates | Buy → Buy | Get Alert |
04/18/2023 | Buy Now | -86.6% | Needham | Joseph Stringer51% | → $60 | Reiterates | → Buy | Get Alert |
03/24/2023 | Buy Now | -73.2% | HC Wainwright & Co. | Ed Arce60% | → $120 | Reiterates | → Buy | Get Alert |
03/23/2023 | Buy Now | -73.2% | HC Wainwright & Co. | Ed Arce60% | $130 → $120 | Maintains | Buy | Get Alert |
03/08/2023 | Buy Now | -77.67% | Cantor Fitzgerald | Louise Chen56% | → $100 | Reiterates | → Overweight | Get Alert |
03/01/2023 | Buy Now | -70.97% | HC Wainwright & Co. | Ed Arce60% | → $130 | Reiterates | → Buy | Get Alert |
01/25/2023 | Buy Now | -70.97% | HC Wainwright & Co. | Ed Arce60% | $120 → $130 | Maintains | Buy | Get Alert |
05/12/2022 | Buy Now | -73.2% | HC Wainwright & Co. | Ed Arce60% | $150 → $120 | Maintains | Buy | Get Alert |
The latest price target for Cidara Therapeutics (NASDAQ:CDTX) was reported by Citizens Capital Markets on March 12, 2025. The analyst firm set a price target for $46.00 expecting CDTX to rise to within 12 months (a possible 105.45% upside). 20 analyst firms have reported ratings in the last year.
The latest analyst rating for Cidara Therapeutics (NASDAQ:CDTX) was provided by Citizens Capital Markets, and Cidara Therapeutics initiated their market outperform rating.
The last upgrade for Cidara Therapeutics Inc happened on August 14, 2024 when HC Wainwright & Co. raised their price target to $24. HC Wainwright & Co. previously had a neutral for Cidara Therapeutics Inc.
There is no last downgrade for Cidara Therapeutics.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cidara Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cidara Therapeutics was filed on March 12, 2025 so you should expect the next rating to be made available sometime around March 12, 2026.
While ratings are subjective and will change, the latest Cidara Therapeutics (CDTX) rating was a initiated with a price target of $0.00 to $46.00. The current price Cidara Therapeutics (CDTX) is trading at is $22.39, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.